<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05093478</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-19-0333</org_study_id>
    <nct_id>NCT05093478</nct_id>
  </id_info>
  <brief_title>The Prevalence of Local Immunoglobulin E (IgE) Elevation and Its Effect on Intranasal Capsaicin Therapy in the Non-allergic Rhinitis Population</brief_title>
  <official_title>The Prevalence of Local IgE Elevation and Its Effect on Intranasal Capsaicin Therapy in the Non-allergic Rhinitis Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Academy of Otolaryngic Allergy &amp; Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study to determine the therapeutic response of non-allergic rhinitis&#xD;
      patients that have been subtyped as non-allergic rhinitis with local IgE elevation or&#xD;
      non-allergic rhinopathy to intranasal capsaicin based on visual analog scale and optical&#xD;
      rhinometry, to determine the prevalence of non-allergic rhinitis with local IgE elevation in&#xD;
      this study's cohort of patients with non-allergic rhinitis identified by rhinitis history and&#xD;
      negative skin testing for allergic rhinitis, and to determine the change, if any, in&#xD;
      intranasal IgE levels after capsaicin treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in nasal symptoms of rhinorrhea as measured by the visual analog scale (VAS)</measure>
    <time_frame>baseline, 4 weeks post treatment, 12 weeks post treatment</time_frame>
    <description>Results range from 0-10, higher number indicating a worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in nasal obstruction as measured by the visual analog scale (VAS)</measure>
    <time_frame>baseline, 4 weeks post treatment, 12 weeks post treatment</time_frame>
    <description>Results range from 0-10, higher number indicating a worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in nasal itching as measured by the visual analog scale (VAS)</measure>
    <time_frame>baseline, 4 weeks post treatment, 12 weeks post treatment</time_frame>
    <description>Results range from 0-10, higher number indicating a worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in nasal sneezing as measured by the visual analog scale (VAS)</measure>
    <time_frame>baseline, 4 weeks post treatment, 12 weeks post treatment</time_frame>
    <description>Results range from 0-10, higher number indicating a worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in maximum optical density determined via optical rhinometry</measure>
    <time_frame>baseline, 12 weeks post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in local IgE level</measure>
    <time_frame>baseline, 12 weeks post treatment</time_frame>
    <description>The IgE levels will be obtained from the brush biopsy of the inferior turbinates</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Non-allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal capsaicin</intervention_name>
    <description>Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topical lidocaine</intervention_name>
    <description>The nose will be pre-treated with topical lidocaine 15 minutes before each application</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic rhinitis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active smoker&#xD;
&#xD;
          -  Anatomic source of nasal symptoms&#xD;
&#xD;
          -  Chronic rhinosinusitis or other nasal infection&#xD;
&#xD;
          -  History of sinonasal malignancy&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Use of medication affecting nasal function (topical steroids, topical&#xD;
             anticholinergics, oral antihistamines) in the previous 4 weeks&#xD;
&#xD;
          -  Use or abuse of nasal decongestants.&#xD;
&#xD;
          -  Positive skin prick test for allergic rhinitis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baily A LeConte, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bailey A LeConte, MD</last_name>
    <phone>(713) 500-6500</phone>
    <email>Bailey.A.LeConte@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amber Luong, MD</last_name>
    <phone>(713) 500-5410</phone>
    <email>Amber.U.Luong@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bailey A LeConte, MD</last_name>
      <phone>713-500-6500</phone>
      <email>Bailey.A.LeConte@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amber Luong, MD</last_name>
      <phone>(713) 500-5410</phone>
      <email>Amber.U.Luong@uth.tmc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 14, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Bailey Ann LeConte</investigator_full_name>
    <investigator_title>Chief Resident</investigator_title>
  </responsible_party>
  <keyword>rhinorrhea</keyword>
  <keyword>congestion</keyword>
  <keyword>sneezing</keyword>
  <keyword>itching</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Common Cold</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Capsaicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

